immunotherapy

Johns Hopkins Student Wins Top Prize For Research on Lethal Brain Tumors in Children

Johns Hopkins Student Wins Top Prize For Research on Lethal Brain Tumors in Children

Posted by  | Childhood Cancer, Research

Johns Hopkins undergraduate student Sabrina Wang won first place in a competition among 125 students for her research on a lethal type of pediatric brain tumor called atypical teratoid/rhabdoid tumors (AT/RT), the most common brain tumor type in infants. The award was presented at the AACR 2017 annual meeting in Washington, D.C., on April 2.(...)

Training the next generation of cancer immunotherapy experts

Training the next generation of cancer immunotherapy experts

Posted by  | treatment

Jiajia Zhang was a trained oncologist in China when she read news about former Vice President Joe Biden's visit to Johns Hopkins and the launch of the Bloomberg-Kimmel Institute. "I want to make more of an impact in patients' lives, and I believe immunotherapy is the future of cancer treatment," says Zhang. She decided to(...)

Making Real and Measureable Progress with Immunotherapy

Posted by  | treatment

--This blog post celebrates the one-year anniversary of the launch of the Bloomberg~Kimmel Institute for Cancer Immunotherapy. When we launched the Bloomberg~Kimmel Institute for Cancer Immunotherapy last March, we committed to accelerate the progress of immunotherapies in a real and measurable way, taking advantage of its ability to produce unprecedented and durable cancer regressions. We(...)

Top Questions Ahead for Cancer Immunotherapy

Top Questions Ahead for Cancer Immunotherapy

Posted by  | Research

A decade ago, Suzanne Topalian, M.D., led a team of researchers who made an astonishing contribution to how cancer is fought. Many cancers can “put the brakes” on the body’s immune cells — cells that would normally storm into a tumor and destroy it. Topalian, director of the Melanoma Program at the Johns Hopkins Kimmel(...)

Research from Bloomberg-Kimmel Institute Among Best of #ASCO2017

Posted by  | Research

More than 20 years ago, when Johns Hopkins scientists Bert Vogelstein, Ken Kinzler and their colleagues linked certain cancers to mutations in genes that repair DNA, they may not have imagined that their findings would spark an idea that has become a crystal ball for predicting whether immunotherapy is more likely to work in a person(...)

5 Things We Learned About Immunotherapy This Year

Posted by  | Research

Immunotherapy has become one of the hottest areas of cancer research, and the number of cancers successfully treated by immunotherapy is growing. Nearing the end of 2016, there are now four FDA-approved immunotherapy drugs that target immune system checkpoints to treat six types of cancer. We asked Drew Pardoll, M.D., Ph.D., director of the Bloomberg~Kimmel(...)

President Obama Signs 21st Century Cures Act

Posted by  | Research

A ceremony was held yesterday at the White House to sign the 21st Century Cures Act, which authorizes $4.8 billion in National Institutes of Health funding for a broad range of biomedical initiatives, including cancer and precision medicine. Immunotherapy patient Stefani Joho [watch a video of Stefani's story] and Dr. Elizabeth Jaffee, deputy director of the(...)

Immunotherapy drug staves off lung cancer better than chemo in some newly treated patients

Immunotherapy drug staves off lung cancer better than chemo in some newly treated patients

Posted by  | treatment

In a head-to-head comparison between the immunotherapy drug pembrolizumab and standard chemotherapy as a first-line therapy for advanced nonsmall cell lung cancer, patients taking pembrolizumab had a 50 percent greater drop in the risk of death or disease progression and a four-month greater increase in progression-free survival compared with those who took chemotherapy. A report on(...)

Studies track how the immune system responds to tumors

Studies track how the immune system responds to tumors

Posted by  | Research

The University of Chicago and Johns Hopkins' Bloomberg~Kimmel Institute for Cancer Immunotherapy  have published a pair of studies looking at biomarkers involved in the immune system's response to tumors in the Nov. 7 issue of the Proceedings of the National Academy of Sciences. The University of Chicago studies are explained here. For the Johns Hopkins(...)

A perspective on an immunotherapy clinical trial

Posted by  | Patient Stories

This blog post was written by Kristina Baum, who has melanoma and is participating in a clinical trial on immunotherapy at the Johns Hopkins Kimmel Cancer Center. For more information on Kristina's story, watch her interview with Denise Grady on the New York Times' Facebook page or follow her on Twitter at @kristinabaum. For the post,(...)